WO2016047797A1 - 注射用医薬組成物 - Google Patents
注射用医薬組成物 Download PDFInfo
- Publication number
- WO2016047797A1 WO2016047797A1 PCT/JP2015/077223 JP2015077223W WO2016047797A1 WO 2016047797 A1 WO2016047797 A1 WO 2016047797A1 JP 2015077223 W JP2015077223 W JP 2015077223W WO 2016047797 A1 WO2016047797 A1 WO 2016047797A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- composition according
- ala
- leu
- pro
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 43
- 238000002347 injection Methods 0.000 title abstract description 25
- 239000007924 injection Substances 0.000 title abstract description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 236
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 41
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 41
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 40
- 150000003839 salts Chemical class 0.000 claims abstract description 37
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 35
- QMUKFZMAYHSADK-MZDDNWLQSA-N (2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(C)C)C(O)=O QMUKFZMAYHSADK-MZDDNWLQSA-N 0.000 claims abstract description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims description 119
- 238000002360 preparation method Methods 0.000 claims description 79
- 239000007788 liquid Substances 0.000 claims description 58
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 48
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 44
- 229940022399 cancer vaccine Drugs 0.000 claims description 41
- 238000009566 cancer vaccine Methods 0.000 claims description 41
- 239000003002 pH adjusting agent Substances 0.000 claims description 39
- 239000000725 suspension Substances 0.000 claims description 38
- 150000001413 amino acids Chemical group 0.000 claims description 35
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 34
- 235000010355 mannitol Nutrition 0.000 claims description 23
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 19
- 229930182817 methionine Natural products 0.000 claims description 18
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 17
- 239000011975 tartaric acid Substances 0.000 claims description 17
- 235000002906 tartaric acid Nutrition 0.000 claims description 17
- 229930195725 Mannitol Natural products 0.000 claims description 13
- 239000000594 mannitol Substances 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 9
- 238000004090 dissolution Methods 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- 238000000034 method Methods 0.000 description 28
- 239000008215 water for injection Substances 0.000 description 25
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 22
- 108010075704 HLA-A Antigens Proteins 0.000 description 22
- 239000002671 adjuvant Substances 0.000 description 21
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 21
- 102000040856 WT1 Human genes 0.000 description 20
- 108700020467 WT1 Proteins 0.000 description 20
- 229960004452 methionine Drugs 0.000 description 19
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 17
- 229920005549 butyl rubber Polymers 0.000 description 17
- 238000011830 transgenic mouse model Methods 0.000 description 17
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 16
- 241000699660 Mus musculus Species 0.000 description 16
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 16
- 101150084041 WT1 gene Proteins 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- -1 inorganic acid salts Chemical class 0.000 description 8
- 239000004310 lactic acid Substances 0.000 description 8
- 235000014655 lactic acid Nutrition 0.000 description 8
- 210000004989 spleen cell Anatomy 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 235000015165 citric acid Nutrition 0.000 description 7
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 229960003194 meglumine Drugs 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 238000007789 sealing Methods 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 229960000281 trometamol Drugs 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 229930064664 L-arginine Natural products 0.000 description 6
- 235000014852 L-arginine Nutrition 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 238000010647 peptide synthesis reaction Methods 0.000 description 6
- 108010081208 RMFPNAPYL Proteins 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 239000012931 lyophilized formulation Substances 0.000 description 5
- 150000007530 organic bases Chemical class 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- WTKQMHWYSBWUBE-UHFFFAOYSA-N (3-nitropyridin-2-yl) thiohypochlorite Chemical compound [O-][N+](=O)C1=CC=CN=C1SCl WTKQMHWYSBWUBE-UHFFFAOYSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 150000007529 inorganic bases Chemical class 0.000 description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000011510 Elispot assay Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 3
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 3
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- 229930195722 L-methionine Natural products 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 108091005601 modified peptides Proteins 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 102000046004 human WT1 Human genes 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- OVTLOLNDKQUMRH-QMMMGPOBSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-[(3-nitropyridin-2-yl)disulfanyl]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CSSC1=NC=CC=C1[N+]([O-])=O OVTLOLNDKQUMRH-QMMMGPOBSA-N 0.000 description 1
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 1
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 1
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical class CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 1
- 239000002524 monosodium citrate Substances 0.000 description 1
- 235000018342 monosodium citrate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- DGPIGKCOQYBCJH-UHFFFAOYSA-M sodium;acetic acid;hydroxide Chemical compound O.[Na+].CC([O-])=O DGPIGKCOQYBCJH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 125000000647 trehalose group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-O triethanolammonium Chemical class OCC[NH+](CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-O 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
Definitions
- the present invention relates to an injectable pharmaceutical composition
- a WT1 protein-derived cancer antigen peptide belonging to the field of cancer immunotherapy and having cytotoxic T cell-inducing activity comprising a WT1 protein-derived cancer antigen peptide belonging to the field of cancer immunotherapy and having cytotoxic T cell-inducing activity.
- the WT1 protein-derived cancer antigen peptide is a partial peptide derived from human WT1 protein (SEQ ID NO: 2) consisting of 449 amino acids, specifically a peptide having 8 to 12 amino acids or a dimer thereof, Antigen recognition by major histocompatibility antigen (Major Histocompatibility Complex, MHC) class I antigen and cytotoxic T cells (cytotoxic T lymphocyte, Cytotoxic T-cell, hereinafter referred to as CTL) Containing the peptide to be produced.
- MHC major histocompatibility Complex
- CTL cytotoxic T cells Containing the peptide to be produced.
- MHC is called human leukocyte type antigen (HLA) in humans.
- a partial peptide consisting of an amino acid sequence represented by Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu (SEQ ID NO: 3) (WT1 126-134 peptide);
- the second amino acid from the N-terminal of the partial peptide (WT1 235-243 peptide) consisting of the amino acid sequence represented by Cys-Met-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 6)
- a modified peptide modified from methionine to tyrosine ie, a peptide having an amino acid sequence represented by Cys-Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu (SEQ ID NO: 5)
- HLA It is reported to be useful as a peptide for inducing CTL (see Patent Documents 1 to 4).
- Patent Documents 1 to 4 see Patent Documents 1 to 4).
- Trp-Ala-Pro-Val-Leu-Asp-Phe-Ala-Pro-Pro-Gly-Ala-Ser-Ala-Tyr-Gly-Ser-Leu SEQ ID NO:
- the partial peptide consisting of the amino acid sequence represented by 1) (WT1 34-51 peptide) itself is useful as a peptide that binds to HLA and induces CTL. It has been reported that there is an effect as a peptide (see Patent Document 5). However, an optimal cancer vaccine composition containing this peptide has not been known.
- WT1 and 126-134 peptides and / or modified WT1 235-243 peptide the optimum cancer vaccine composition comprising an WT1 34-51 peptide, since it is useful as a cancer vaccine, to ensure the stability of these peptides It was expected to develop a formulation.
- the subject of the present invention is a peptide represented by the formula (1) or Trp-Ala-Pro-Val-Leu-Asp-Phe-Ala-Pro-Pro-Gly-Ala-Ser-Ala-Tyr-Gly-Ser-
- An object of the present invention is to provide a stable pharmaceutical composition for injection of a peptide that can be used for the preparation of a cancer vaccine preparation containing a WT1 partial peptide consisting of the amino acid sequence represented by Leu (SEQ ID NO: 1).
- the present inventors have found that trehalose and pH adjustment in a liquid preparation containing the peptide represented by the formula (1) or the WT1 partial peptide having the sequence represented by SEQ ID NO: 1
- the present inventors have found that a liquid agent and / or a lyophilized preparation excellent in formulation stability can be obtained by containing an agent, and the present invention has been completed.
- the present invention relates to the following.
- Item 1 Injectable pharmaceutical composition
- Item 2 The composition according to Item 1, wherein the component (a) is one or more peptides selected from a peptide represented by the formula (1) and a salt thereof.
- Item 3. The composition according to Item 2, further comprising mannitol.
- Item 4. The composition according to Item 3, wherein the mannitol is D-mannitol.
- Item 5. The composition according to any one of Items 2 to 4, further comprising methionine.
- Item 6. The composition according to Item 5, wherein the methionine is L-methionine.
- Item 7. The composition according to any one of Items 2 to 6, wherein the pH is 1 to 3.
- Item 8 The composition according to any one of Items 2 to 7, wherein the composition is a liquid or suspension and the content of the component (b) is 1 to 100 mg / g.
- Item 9 The composition according to any one of Items 3 to 8, wherein the composition is a liquid or a suspension, and the content of mannitol is 1 to 50 mg / g.
- Item 10 The composition according to any one of Items 5 to 9, wherein the composition is a liquid or a suspension, and the content of methionine is 1 to 30 mg / g.
- Component (a) is represented by Trp-Ala-Pro-Val-Leu-Asp-Phe-Ala-Pro-Pro-Gly-Ala-Ser-Ala-Tyr-Gly-Ser-Leu (SEQ ID NO: 1)
- Item 2 The composition according to Item 1, which is one or more peptides selected from peptides consisting of amino acid sequences and salts thereof.
- Item 12. The composition according to Item 11, further comprising a solubilizing agent.
- Item 13 The composition according to Item 12, wherein the dissolution aid is citric acid, lactic acid, tartaric acid, acetic acid, or trifluoroacetic acid.
- Item 14 The composition according to Item 12, wherein the dissolution aid is tartaric acid.
- Item 15 The composition according to any one of Items 12 to 14, wherein the pH is 2 to 3.
- Item 16 The composition according to Item 11, wherein the pH is 5 to 10.
- Item 17 The composition according to any one of Items 11 to 16, wherein the composition is a liquid or suspension and the content of the component (b) is 1 to 100 mg / g.
- Item 18 The composition according to any one of Items 12 to 15, wherein the composition is a solution or a suspension, and the content of the solubilizing agent is 0.1 to 10 mg / g.
- Item 19 The composition according to any one of Items 11 to 18, wherein the acid used as the pH adjuster is a weak acid.
- Component (a) is one or more peptides selected from the peptide represented by formula (1) and salts thereof, and Trp-Ala-Pro-Val-Leu-Asp-Phe-Ala-Pro-Pro-Gly A peptide comprising the amino acid sequence represented by -Ala-Ser-Ala-Tyr-Gly-Ser-Leu (SEQ ID NO: 1) and one or more peptides selected from salts thereof, Item 2.
- Item 21 The composition according to Item 20, further comprising mannitol.
- Item 22 The composition according to Item 20 or 21, further comprising methionine.
- Item 23 The composition according to any one of Items 20 to 22, further comprising a solubilizing agent.
- Item 24 The composition according to any one of Items 20 to 23, wherein the pH is 2 to 3.
- Item 25 The composition according to any one of Items 20 to 24, wherein the composition is a liquid or a suspension, and the content of the component (b) is 1 to 100 mg / g.
- Item 26 The composition according to any one of Items 21 to 25, wherein the composition is a liquid or suspension, and the content of mannitol is 1 to 50 mg / g.
- Item 27 The composition according to any one of Items 22 to 26, wherein the composition is a liquid or a suspension, and the content of methionine is 1 to 30 mg / g.
- Item 28 The pharmaceutical composition for injection according to any one of Items 23 to 27, wherein the composition is a liquid or a suspension, and the content of the solubilizing agent is 0.1 to 10 mg / g. .
- Item 29 A lyophilized preparation obtained by lyophilizing the composition according to any one of Items 8 to 10, 17, 18, and 25 to 28.
- Item 30 The composition according to any one of Items 1 to 18, wherein the composition is a solution, a suspension, or a lyophilized formulation.
- Item 31 The pharmaceutical composition according to any one of Items 1 to 7, 11 to 16, 19 to 24, and 30, wherein the composition is a liquid or a suspension.
- Item 32 is produced by adding the composition according to any one of Items 11 to 15 in the form of a liquid agent to the composition according to any one of Items 2 to 7 that is in the form of a lyophilized formulation.
- Item 25 The composition according to any one of Items 20 to 24.
- Item 33 The composition according to item 32, which is a liquid or suspension.
- Item 34 A cancer vaccine composition comprising the composition according to any one of Items 1 to 28 and 30 to 33.
- Item 35 The cancer vaccine composition according to Item 34, further comprising an adjuvant.
- Item 36 The cancer vaccine composition according to Item 35, wherein the adjuvant is montanide.
- Item 39 The composition according to any one of Items 2 to 7 which is in the form of a lyophilized formulation, and the composition according to any one of Items 11 to 15 which is in the form of a liquid agent.
- Item 25 A method for producing the composition according to any one of Items 20 to 24.
- Item 40 A method for producing a cancer vaccine composition, comprising adding a composition obtained by the method according to Item 39 to an adjuvant.
- Item 41 The composition according to Item 18, wherein the content of component (b) is 1 to 100 mg / g.
- Item 42 The pharmaceutical composition for injection according to any one of Items 1 to 18, wherein the pH adjuster is hydrochloric acid and / or sodium hydroxide.
- a cancer vaccine composition stably containing the peptide of the present invention having cytotoxic T cell-inducing activity can be produced, and a cancer vaccine having excellent formulation stability Can be prepared.
- a lyophilized preparation in which the peptide is stably maintained can be prepared.
- FIG. 1 is a graph showing the results of Test Example 4.
- the vertical axis represents the number of cells that reacted in the number of seeded cells, and the horizontal axis represents the peptide pulsed in vitro.
- the black bars in FIG. 1 show the results of culturing spleen cells derived from HLA-A * 02: 01 transgenic mice while pulsing the peptide represented by SEQ ID NO: 3, and the white bars show the results of non-pulse culture.
- FIG. 2 is a graph showing the results of Test Example 4.
- the vertical axis represents the number of cells that reacted in the number of seeded cells, and the horizontal axis represents the peptide pulsed in vitro.
- the black bar in FIG. 2 shows the result of culturing splenocytes derived from the HLA-A * 24: 02 transgenic mouse while pulsing the peptide represented by SEQ ID NO: 5, and the white bar is cultured without pulse. Results are shown.
- the “injectable pharmaceutical composition” in the present invention refers to a composition comprising the peptide of the present invention and one or more components excluding the peptide.
- a cancer vaccine composition can be prepared by mixing an injectable pharmaceutical composition with various adjuvants.
- the pharmaceutical composition for injection of the present invention can be provided in the form of a solution, suspension, lyophilized preparation or the like.
- the “solution” is obtained by dissolving each component contained in the “injectable pharmaceutical composition” in a solvent.
- a solvent for the “solvent” in the present invention, water is usually mentioned, but pharmacologically acceptable solvents such as propylene glycol and polyethylene glycol can be partially mixed with water as long as they are not affected by the effects of the invention. .
- it is water.
- a solution obtained by condensing and dissolving a “lyophilized preparation” described later is also included in the “solution” in the present invention.
- the “suspension” in the present invention is obtained by mixing and suspending each component contained in the “injectable pharmaceutical composition” in a dispersion medium.
- a dispersion medium water is usually used, but a pharmacologically acceptable solvent such as propylene glycol and polyethylene glycol may be partially mixed with water as long as the effect of the invention is not affected. it can. Preferably it is water.
- a product obtained by condensing and suspending a “lyophilized preparation” described later is also included in the “suspension” in the present invention.
- the “lyophilized preparation” in the present invention is a product obtained by lyophilizing the “solution” or “suspension” in the present invention. Usually, it is performed to improve the chemical and physical stability of the peptide in the “solution” or “suspension”.
- an appropriate amount of water is added and stirred to form a liquid or suspension, and then mixed with various adjuvants to prepare a cancer vaccine composition.
- the “peptide” in the present invention is a cancer antigen peptide for preparing a cancer vaccine, the peptide represented by the formula (1), and Trp-Ala-Pro-Val-Leu-Asp-Phe-Ala-Pro A peptide selected from the group consisting of peptides consisting of the amino acid sequence represented by -Pro-Gly-Ala-Ser-Ala-Tyr-Gly-Ser-Leu (SEQ ID NO: 1), or a salt thereof .
- the left side of the peptide is the N-terminus, and each amino acid symbol indicates the following amino acid residue.
- Ala or A alanine residue Arg or R: Arginine residue Asn or N: Asparagine residue Asp or D: Aspartic acid residue Cys or C: Cysteine residue Gln or Q: Glutamine residue Glu or E: Glutamic acid residue Gly or G: Glycine residue His or H: histidine residue Ile or I: isoleucine residue Leu or L: Leucine residue Lys or K: Lysine residue Met or M: methionine residue Phe or F: phenylalanine residue Pro or P: proline residue Ser or S: Serine residue Thr or T: Threonine residue Trp or W: Tryptophan residue Tyr or Y: tyrosine residue Val or V: valine residue
- “Peptide represented by the formula (1)” refers to Cys ⁇ , which has a cysteine residue bonded to the N-terminus of Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu (SEQ ID NO: 3).
- Leu SEQ ID NO: 5
- the peptide consisting of the amino acid sequence represented by Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu is a protein (specific example) of the Wilms tumor tumor suppressor gene WT1. Specifically, it consists of 9 consecutive amino acids from the N-terminal of the human WT1 protein (SEQ ID NO: 2) consisting of 449 amino acids from the 126th arginine (Arg) to the 134th leucine (Leu). It is a partial peptide (WT1 126-134 peptide).
- the peptide is a peptide that is presented to MHC class I antigen and recognized by CTL.
- the peptide consisting of the amino acid sequence represented by Cys-Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu is 243 from 235th cysteine (Cys) from the N-terminal of WT1 protein.
- Cys 235th cysteine
- the peptide is a peptide that is presented to MHC class I antigen and recognized by CTL.
- the “peptide” is a partial peptide (WT1 34-51 peptide) consisting of 18 amino acids from the 34th tryptophan (Trp) to the 51st leucine (Leu) from the N-terminus of the WT1 protein.
- the peptide is a peptide that is presented to MHC class II antigen and induces WT1-specific helper T cells.
- the salt of the peptide consisting of the peptide represented by the formula (1) and the amino acid sequence represented by SEQ ID NO: 1 is not particularly limited as long as it is a pharmaceutically acceptable salt.
- Examples of the “salt” in the present invention include acid addition salts and base addition salts.
- the acid addition salts include inorganic acid salts such as hydrochloride, hydrobromide, sulfate, hydroiodide, nitrate and phosphate, citrate, oxalate, acetate, formate , Propionate, benzoate, trifluoroacetate, maleate, tartrate, methanesulfonate, benzenesulfonate, paratoluenesulfonate, and other organic acid salts.
- inorganic acid salts such as hydrochloride, hydrobromide, sulfate, hydroiodide, nitrate and phosphate, citrate, oxalate, acetate, formate , Propionate, benzoate, trifluoroacetate, maleate, tartrate, methanesulfonate, benzenesulfonate, paratoluenesulfonate, and other organic acid salts.
- Inorganic base salts such as sodium salt, potassium salt, calcium salt, magnesium salt, ammonium salt, organic base salts such as triethylammonium salt, triethanolammonium salt, pyridinium salt, diisopropylammonium salt, and the like, and arginine, Examples thereof include amino acid salts such as basic or acidic amino acids such as aspartic acid and glutamic acid.
- a peptide represented by the formula (1) or a salt thereof, a peptide consisting of the amino acid sequence represented by SEQ ID NO: 1 or a hydrate of the salt thereof, a solvate such as an ethanol solvate is also included in the peptide of the present invention. included. Furthermore, the peptide of the present invention also includes all diastereomers and enantiomers of the peptide represented by the formula (1), and any stereoisomers or salts thereof, and crystal forms of all embodiments.
- the peptide represented by the formula (1) or a salt thereof can be produced by the method described in the examples of the present specification or a known method (see Patent Documents 2 to 4).
- the peptide consisting of the amino acid sequence represented by SEQ ID NO: 1 or a salt thereof can be produced by a known method (see Patent Document 5).
- the peptide of this invention may be manufactured by the method normally used in the said technical field. See, for example, Peptide Synthesis, Interscience, New York, 1966; The proteins, Vol 2, Academic Press Inc. , New York, 1976; peptide synthesis, Maruzen Co., Ltd., 1975; peptide synthesis fundamentals and experiments, Maruzen Co., Ltd.
- the peptide of the present invention obtained by the above method is a free form
- the free form can be converted into an appropriate salt by a known method or a method analogous thereto, and conversely, the peptide of the present invention is converted into a salt.
- the salt can be converted into a free form or other salt by a known method or a method analogous thereto.
- the pharmaceutical composition for injection of the present invention may contain the peptide represented by the formula (1) and one salt thereof alone, or the peptide and one or more salts thereof, or two or more salts. May be contained (hereinafter may be collectively referred to as “peptide (1)”).
- the pharmaceutical composition for injection of the present invention may contain a peptide consisting of the amino acid sequence represented by SEQ ID NO: 1 and one salt thereof alone, or the peptide and one or more kinds thereof.
- a salt thereof or a salt of two or more kinds of the peptides may be contained (hereinafter sometimes referred to collectively as “peptide (2)”).
- the pharmaceutical composition for injection of the present invention may contain both peptide (1) and peptide (2).
- the content of the peptide of the present invention per weight of the liquid formulation of the present invention is The content is not particularly limited and may be any content that is pharmacologically or physically acceptable.
- the preferable content of peptide (1) (when two or more peptides are included, the total amount thereof) is 0.5 mg to 200 mg / g, more preferably 0. Examples include 5 mg to 100 mg / g, 0.5 mg to 50 mg / g, and 1 mg to 25 mg / g, and may be selected according to the purpose.
- the preferable content of peptide (2) (when two or more peptides are included, the total amount thereof) is, for example, 0.05 mg to 200 mg / g, more preferably 0.05 mg to 100 mg / g. , 0.05 mg to 50 mg / g, and 0.1 mg to 25 mg / g, and may be selected according to the purpose.
- the weight ratio of peptide (1) to peptide (2) is appropriately selected within the range of 1: 0.1 to 1: 5. Can be done.
- the content per volume of the peptide of the present invention is not particularly defined.
- the freeze-dried preparation of the present invention is obtained by freeze-drying the liquid preparation of the present invention, and the content of the peptide only needs to satisfy the content of the liquid preparation.
- the concentration of the present invention is increased. A liquid formulation can be obtained.
- the pharmaceutical composition for injection of the present invention comprises the following components (b) and (c) in addition to the above-described peptide of the present invention (component (a)): (B) Trehalose or trehalose hydrate (c) It contains a pH adjuster.
- trehalose represents a kind of disaccharide formed by combining 1,1-glycoside with glucose.
- Trehalose may be an anhydride or a hydrate thereof.
- Trehalose hydrate is preferred.
- the injectable pharmaceutical composition of the present invention may contain trehalose in the form of either an anhydride or a hydrate thereof alone or in combination of two or more thereof.
- the content per weight in the composition of trehalose is not particularly specified, but the content per weight in the liquid preparation of the present invention (if contained in two or more forms, these As a total amount) of 1 to 50 mg / g, 1 to 70 mg / g, 1 to 100 mg / g, 1 to 150 mg / g, 1 to 200 mg / g, 3 to 50 mg / g, 3 to 70 mg / g, 3 to 100 mg / g, 3 to 150 mg / g, 3 to 200 mg / g, 5 to 50 mg / g, 5 to 70 mg / g, 5 to 100 mg / g, 5 to 150 mg / g, 5 to 200 mg / g, etc. Can be mentioned.
- the “pH adjuster” in the present invention represents a pH adjuster generally used in pharmaceutical preparations.
- inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, disodium phosphate, dipotassium phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate and trisodium phosphate, or salts thereof, nitric acid, acetic acid, Citric acid, tartaric acid, lactic acid, maleic acid, sodium acetate hydrate, anhydrous sodium acetate, sodium citrate hydrate, sodium dihydrogen citrate, sodium tartrate and other organic acids or salts thereof, sodium hydroxide, potassium hydroxide
- inorganic bases such as aqueous ammonia, or organic bases such as trometamol, histidine, L-arginine, and meglumine.
- citric acid lactic acid, tartaric acid, hydrochloric acid, sulfuric acid, nitric acid, sodium hydroxide and potassium hydroxide, or trimetamol, histidine, L-arginine, and meglumine, more preferably tartaric acid, hydrochloric acid, and sodium hydroxide, or Trometamol, L-arginine, and meglumine.
- a weak acid is preferable as the acid in the pH adjuster.
- the pH adjuster is added to adjust the pH of the liquid preparation of the present invention to a pH range that can ensure the stability of the peptide of the present invention. Since the pH range that can ensure the stability of the peptide of the present invention varies depending on the type of the peptide of the present invention contained in the liquid preparation, as described later, a pH adjuster corresponding to each is used.
- the pH of the liquid preparation of the present invention is 1-10.
- the pH is preferably 1 to 4, more preferably 1 to 3, and most preferably 2 to 3 from the viewpoint of solubility and stability.
- the pH is preferably 5 to 10 from the viewpoint of solubility.
- the preferred pH when the liquid preparation is a liquid, the preferred pH is 1.5 to 4.5, 1.5 to 3.5, 1.5 to 3.0, 2.0 to 3.0. In the case of a suspension, preferred pH is 4 to 9, 4 to 6, 5 to 9.
- the pH of the liquid preparation of the present invention when the injectable pharmaceutical composition of the present invention contains only the peptide (2), the pH of the liquid preparation of the present invention is 2 to 10, and more specific ranges are 2 to 3, 3 to 9, 6-9, 7. From the viewpoint of stability, the preferred pH is 5 to 10, more preferably 6 to 8.
- the pH of the liquid preparation of the present invention is 2-10.
- liquid preparation is a liquid preparation
- preferred pH is 2 to 4, 2 to 3, 1.7 to 3.2, and 1.5 to 3.5 from the viewpoint of stability. Numbers in this specification are expressed by rounding off the digit one digit below. For example, if it is 2, it means 1.5 or more and less than 2.5.
- the pH is adjusted to the desired pH by adding an inorganic acid or an organic acid, etc. Can do.
- an inorganic acid and organic acid those described above can be used.
- an inorganic base or an organic base can be used as the pH adjuster when the pH value is lower than the desired pH range.
- the inorganic base and organic base those described above can be used.
- the pharmaceutical composition for injection of the present invention contains only the peptide (2), it is preferable to use an inorganic base or an organic base as a pH adjuster.
- the content per weight in the organic base composition is not particularly specified, but the content per weight in the liquid preparation of the present invention is 1 to 100 mg / g, 1 to 50 mg / g, 1 to 150 mg / g, 5 to 100 mg / g, 5 to 50 mg / g, 5 to 150 mg / g, 10 to 100 mg / g, 10 to 50 mg / g, 10 to 150 mg / g, and the like. .
- the composition may contain mannitol.
- “Mannitol” in the present invention is a kind of sugar alcohol, which is classified into hexitol and corresponds to a reduced form of mannose. Mannitol has optical isomers and includes D-form, L-form and DL-form, and any of these does not affect the effect of the present invention. Preferred is D-mannitol which is abundant in nature. In addition, mannitol has a plurality of crystal systems, and any of these does not affect the effect of the present invention.
- the content per weight in the mannitol composition is not particularly specified, but the content per weight in the liquid preparation of the present invention is 1 to 20 mg / g, 1 to 30 mg. / G, 1-50 mg / g, 3-20 mg / g, 3-30 mg / g, 5-20 mg / g, 5-30 mg / g and the like.
- the composition for injection of the present invention contains the peptide (2) as the component (a), the solubility of the peptide becomes unstable. Therefore, the composition preferably further contains a solubilizing agent.
- a solubilizing agent for example, an organic acid can be used.
- a solubilizing agent it can be quickly dissolved in the dissolving step of the peptide (2) as a liquid agent.
- the solubilizer include citric acid, lactic acid, tartaric acid, acetic acid, and trifluoroacetic acid.
- the content per weight in the composition of the solubilizing agent is not particularly defined, but the content per weight in the liquid preparation of the present invention is 1 to 5 mg / g, 1 -10 mg / g, 1-15 mg / g, 1-20 mg / g, 3-10 mg / g, 3-15 mg / g, 3-20 mg / g, 5-10 mg / g, 5-15 mg / g, 5-20 mg / G, 0.1-5 mg / g, 0.1-10 mg / g, 0.1-15 mg / g, 0.1-20 mg / g, 0.3-10 mg / g, 0.3-15 mg / g 0.3 to 20 mg / g, 0.5 to 10 mg / g, 0.5 to 15 mg / g, and 0.5 to 20 mg / g.
- the composition further contains methionine from the viewpoint of the stability of the peptide when prepared as a cancer vaccine composition. It is desirable. By blending methionine, oxidation of the methionine residue contained in peptide (1) can be suppressed when it is prepared as a cancer vaccine composition.
- methionine of the present invention is one of the essential amino acids, and is a hydrophobic amino acid containing a sulfur atom in the side chain. “Methionine” has optical isomers and includes D-form, L-form and DL-form, and any of these does not affect the effect of the present invention.
- the content per weight in the methionine composition is not particularly specified, but preferably the content per weight in the liquid preparation of the present invention is 1 to 5 mg / g, 1 ⁇ 10 mg / g, 1 ⁇ 20 mg / g, 1 ⁇ 30 mg / g, 3 ⁇ 10 mg / g, 3 ⁇ 20 mg / g, 3 ⁇ 30 mg / g, 5 ⁇ 10 mg / g, 5 ⁇ 20 mg / g, and 5 ⁇ 30 mg / g etc. are mentioned.
- the pharmaceutical composition for injection of the present invention includes pharmaceutical preparations such as stabilizers, solubilizers, buffers, isotonic agents, etc. Generally used additives can be used.
- the pharmaceutical composition for injection of the present invention can be produced by a method generally used in pharmaceutical production or the like. Specifically, for example, in an environment maintained at a constant temperature of 5 to 25 ° C., water for injection is charged into an appropriate container, and the peptides and additives weighed in advance are added while gently stirring, and finally It can be prepared by adjusting to a desired pH, sterilized by filtration after the preparation, filled in a container such as a glass vial, and sealed with a rubber stopper or the like. In the case of preparing a freeze-dried preparation, the obtained liquid preparation of the present invention may be freeze-dried by a method known per se.
- Each of the peptides of the present invention can be used alone as an antigen peptide for a cancer vaccine, but both the peptide (1) and the peptide (2) can be contained in the cancer vaccine composition.
- Peptide (2) binds to HLA by itself, induces CTL, and also has an effect as a helper peptide when used in combination with peptide (1), so both peptide (1) and peptide (2)
- the cancer vaccine composition containing the compound is expected to have a synergistic vaccine effect.
- one pharmaceutical composition for injection according to the present invention containing both peptides may be mixed with an adjuvant, or two injections according to the present invention containing respective peptides.
- the pharmaceutical composition may be mixed with an adjuvant in triplicate.
- the liquid preparation of the present invention containing both the peptide (1) and the peptide (2) can be prepared directly (in one step) by subjecting both peptides to the above-mentioned production method. It can also be obtained by mixing and preparing both as a separate solution or suspension for production.
- a solution or suspension containing peptide (1) is lyophilized, and a solution or suspension containing peptide (2) is added thereto to freeze containing peptide (1).
- a method of dissolving or suspending the dry preparation is exemplified.
- the lyophilized preparation containing peptide (2) is redissolved or resuspended in a smaller amount of water or the like than the liquid or suspension before lyophilization. It becomes cloudy, and the solution or suspension is added to the lyophilized preparation containing the peptide (1) and dissolved or suspended, so that the solution or suspension has a higher concentration than the solution or suspension before lyophilization. It can be prepared as a liquid.
- a method for preparing a cancer vaccine using the pharmaceutical composition for injection of the present invention is not particularly limited.
- a method for preparing a cancer vaccine by mixing with an appropriate adjuvant A method of preparing a cancer vaccine preparation by drying or the like; a method of preparing a cancer vaccine by mixing the liquid preparation of the present invention with various adjuvants by preparation at the time of use.
- adjuvants include precipitation adjuvants and oil adjuvants.
- Precipitating adjuvant represents an inorganic suspending agent to which a peptide is adsorbed.
- the precipitating adjuvant examples include sodium hydroxide, aluminum hydroxide (Alum), calcium phosphate, aluminum phosphate, alum, pepes, carboxyvinyl polymer, and the like.
- An oily adjuvant represents an oil emulsion in which an aqueous solution containing a peptide is wrapped with mineral oil to form micelles and emulsified.
- Specific examples of the oily adjuvant include liquid paraffin, lanolin, Freund's adjuvant (complete Freund's adjuvant, incomplete Freund's adjuvant), montanide, W / O emulsion (see WO2006 / 078059) and the like.
- Cancer vaccines prepared using the injectable pharmaceutical composition of the present invention are cancers with increased WT1 gene expression levels, for example, blood cancers such as leukemia, myelodysplastic syndrome, multiple myeloma, malignant lymphoma, It can be used for the prevention or treatment of solid cancer such as stomach cancer, colon cancer, lung cancer, breast cancer, germ cell cancer, liver cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical cancer, ovarian cancer, brain tumor, etc. it can.
- blood cancers such as leukemia, myelodysplastic syndrome, multiple myeloma, malignant lymphoma
- solid cancer such as stomach cancer, colon cancer, lung cancer, breast cancer, germ cell cancer, liver cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical cancer, ovarian cancer, brain tumor, etc. it can.
- a cancer vaccine may be prepared according to the purpose.
- parenteral administration is known as a preferable administration route for immunostimulation as a cancer vaccine.
- intraperitoneal administration subcutaneous administration, intradermal administration, intramuscular administration, intravenous administration, nasal administration is known.
- Administration transdermal administration, and the like.
- injection administration such as subcutaneous administration, intradermal administration, intraperitoneal administration, intramuscular administration and the like.
- a peptide comprising the amino acid sequence represented by Trp-Ala-Pro-Val-Leu-Asp-Phe-Ala-Pro-Pro-Gly-Ala-Ser-Ala-Tyr-Gly-Ser-Leu (SEQ ID NO: 1)
- a trehalose hydrate “Trehalose SG (produced by Hayashibara Biochemical Laboratories)” is used as a trehalose, using a peptide produced by a method described in a patent document (WO2010 / 123065).
- D-mannitol “Mannit S (manufactured by Mitsubishi Corporation Foodtech) or D-( ⁇ )-Manitol low in endotoxins (manufactured by Merck)” was used. “Trometamol (manufactured by Nacalai Tesque)” is used as trometamol, “histidine (manufactured by Nacalai Tesque)” is used as histidine, “L-arginine hydrochloride (manufactured by Nacalai Tesque)” is used as L-arginine, and meglumine is used. “Meglumine (Nacalai Tesque)” was used.
- “1 mol / l-hydrochloric acid (manufactured by Nacalai Tesque)” is used as hydrochloric acid
- “1 mol / l-sodium hydroxide solution (manufactured by Nacalai Tesque)” is used as sodium hydroxide.
- sodium dihydrogen “sodium dihydrogen phosphate dihydrate (manufactured by Nacalai Tesque)” was used.
- “(Montanide ISA 51 VG (manufactured by SEPPIC)”) was used as a montanide.
- Step 1 Synthesis of H-Cys (Npys) -Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu-OH (Synthesis of C (Npys) RMFPNAPYL) Fmoc-Leu-Alko-resin (Alko is p-alkoxybenzyl alcohol) 282 mg (manufactured by Watanabe Chemical; 0.71 mmol / g, 0.2 mmol) is used as a starting material to assemble peptide chains by solid phase synthesis by the Fmoc / tBu method. went.
- CS336X type peptide synthesizer manufactured by CS Bio was used, and the Fmoc group was deprotected by treating with 20% piperidine in DMF for 5 minutes and 20 minutes. Coupling of protected amino acids was performed by reacting with 1.05 mmol of protected amino acids, 1 mmol of HBTU, 2 mmol of DIPEA in DMF for 1 hour.
- the obtained resin was washed with DMF and ether and dried under reduced pressure to obtain Boc-Cys (Npys) -Arg (Pmc) -Met-Phe-Pro-Asn (Trt) -Ala-Pro-Tyr (tBu) -Leu -630 mg of Alko-resin was obtained.
- 10 ml of a mixed solution of TFA / H 2 O / TIS 95 / 2.5 / 2.5 was added and shaken at room temperature for 2 hours. After removing the resin by filtration, the reaction solution was concentrated under reduced pressure. The reaction solution was ice-cooled and 50 ml of diethyl ether was added.
- the resulting precipitate was collected by filtration, washed with ether, and then dried under reduced pressure to obtain 217 mg of a crude peptide.
- the obtained crude peptide solution was dissolved in a mixed solution of 20 ml of 20% aqueous acetic acid and 1 ml of acetonitrile and purified by reverse phase HPLC.
- the reaction solution was diluted with 5 ml of 0.1% TFA water and purified by reverse phase HPLC. Pump: manufactured by Shimazu; LC-8A type column: YMC ODS-A 3 cm ⁇ ⁇ 25 cmL, 10 ⁇ m Eluent 1: H 2 O / 0.1% TFA Eluent 2: CH 3 CN / 0.1% TFA Flow rate: 20 ml / min Detection: UV220nm
- the reaction solution was injected into a column equilibrated at a two-component concentration of 25%. Thereafter, the concentration of the two liquids was increased at a rate of 0.25% per minute.
- Example 1 Peptide (1) as a peptide (component (a)), trehalose as a component (b) is dissolved in water for injection so as to have an amount shown in Table 1, and hydrochloric acid and / or as a pH adjuster (component (c)) Alternatively, the pH was adjusted to 1 with sodium hydroxide. After filtration through a 0.2 ⁇ m sterilizing filter, each glass vial was filled with 1 mL and sealed with a butyl rubber stopper. Thereby, the liquid agent of Example 1 was obtained.
- Example 2 As in Example 1, peptide (1), trehalose, pH adjuster (hydrochloric acid and / or sodium hydroxide), and water for injection were prepared in the amounts shown in Table 1 or 2, filled into vials, and sealed with a butyl rubber stopper. The solutions of Examples 2, 3, 5 to 8 and 10 were obtained by sealing. As in Example 1, peptide (1), trehalose, pH adjuster (hydrochloric acid and / or sodium hydroxide), and water for injection were prepared in the amounts shown in Table 1 or 2, filled into vials, and sealed with a butyl rubber stopper. The solution of Examples 4 and 9 is obtained by sealing.
- Example 11 to 19 As in Example 1, as a component (a), a peptide represented by SEQ ID NO: 1 (WAPVLDFAPPGASAYGSL) (hereinafter referred to as peptide (2)), trehalose, a pH adjuster (hydrochloric acid and / or sodium hydroxide), and water for injection.
- peptide (2) a peptide represented by SEQ ID NO: 1
- trehalose a peptide represented by SEQ ID NO: 1
- trehalose a peptide represented by SEQ ID NO: 1
- trehalose a peptide represented by SEQ ID NO: 1
- trehalose a peptide represented by SEQ ID NO: 1
- trehalose a peptide represented by SEQ ID NO: 1
- trehalose a peptide represented by SEQ ID NO: 1
- trehalose a peptide represented by SEQ ID NO: 1
- pH adjuster hydrochloric acid and / or sodium hydroxide
- Example 1 As in Example 1, as a component (a), a peptide represented by SEQ ID NO: 1 (WAPVLDFAPPGASAYGSL) (hereinafter referred to as peptide (2)), trehalose, a pH adjuster (hydrochloric acid and / or sodium hydroxide), and water for injection.
- peptide (2) a peptide represented by SEQ ID NO: 1
- trehalose a peptide represented by SEQ ID NO: 1
- trehalose a peptide represented by SEQ ID NO: 1
- trehalose a peptide represented by SEQ ID NO: 1
- trehalose a peptide represented by SEQ ID NO: 1
- trehalose a peptide represented by SEQ ID NO: 1
- trehalose a peptide represented by SEQ ID NO: 1
- trehalose a peptide represented by SEQ ID NO: 1
- pH adjuster hydrochloric acid and / or sodium hydroxide
- Example 20 to 24 In the same manner as in Example 1, peptide (1), trehalose, D-mannitol, water for injection, pH adjusting agent (hydrochloric acid and / or sodium hydroxide) were prepared in the amounts shown in Table 5, filled into vials, and butyl rubber The solution of Examples 20 to 24 was obtained by sealing with a stopper.
- pH adjusting agent hydroochloric acid and / or sodium hydroxide
- Example 25 Peptide (1) and trehalose are prepared in appropriate amounts in water for injection and added in the amounts shown in Table 6, and after dispersion with a stirrer, the pH is adjusted to 4 with hydrochloric acid and / or sodium hydroxide as a pH adjuster. The suspension of Example 25 was obtained.
- Example 26 to 29 In the same manner as in Example 25, peptide (1) and trehalose were prepared in appropriate amounts in water for injection in the amounts shown in Table 6 and adjusted to the pH in Table 6 using the pH adjusting agent shown in Table 6. The suspensions of Examples 26 to 29 were obtained.
- Example 30 Peptide (2) as a peptide (component (a)), trehalose (component (b)), and trometamol as a pH adjuster (component (c)) are dissolved in water for injection so as to have the amounts shown in Table 7. After filtration through a 0.2 ⁇ m sterile filter, each glass vial is filled with 1 mL and sealed with a butyl rubber stopper. Thereby, the liquid agent of Example 30 was obtained.
- Examples 31 to 34 In the same manner as in Example 30, peptides (2), trehalose, pH adjuster, and water for injection were prepared in the amounts shown in Table 7, filled in vials, and sealed with butyl rubber stoppers. Got.
- Example 35 to 37 As in Example 1, peptide (2), trehalose, solubilizing agents (citric acid, lactic acid, tartaric acid), pH adjusting agent (hydrochloric acid), and water for injection are prepared in the amounts shown in Table 8, and filled into vials. The solutions of Examples 35 to 37 were obtained by sealing with a butyl rubber stopper.
- Example 38 As in Example 1, peptide (2), trehalose, solubilizer (tartaric acid), pH adjuster (hydrochloric acid), and water for injection were prepared in the amounts shown in Table 9 or 10, filled into vials, and butyl rubber stoppers The solution of Examples 38 to 43 was obtained.
- Example 44 As in Example 1, peptide (2), trehalose, solubilizer (tartaric acid), pH adjuster (hydrochloric acid), and water for injection were prepared in the amounts shown in Table 11, filled into vials, and sealed with a butyl rubber stopper As a result, liquid agents of Examples 44 to 47 were obtained.
- Example 48 As in Example 1, peptide (1), trehalose, D-mannitol, water for injection, pH adjuster (hydrochloric acid) were prepared in the amounts shown in Table 12, filled into vials, and sealed with a butyl rubber stopper. Solutions of Examples 48 to 50 were obtained.
- Example 51 As in Example 1, peptide (1), trehalose, D-mannitol, methionine, water for injection, pH adjuster (hydrochloric acid) are prepared in the amounts shown in Table 13, filled into vials, and sealed with a butyl rubber stopper. As a result, a liquid preparation of Example 52 was obtained. As in Example 1, peptide (1), trehalose, D-mannitol, methionine, water for injection, pH adjuster (hydrochloric acid) are prepared in the amounts shown in Table 13, filled into vials, and sealed with a butyl rubber stopper. As a result, the solutions of Examples 51, 53 and 54 are obtained.
- Examples 55 to 58 In the same manner as in Example 1, peptide (2), trehalose, tartaric acid, water for injection, and pH adjuster (hydrochloric acid) were prepared in the amounts shown in Table 14, filled into vials, and sealed with a butyl rubber stopper. 55 and 56 solutions were obtained. In the same manner as in Example 1, peptide (2), trehalose, tartaric acid, water for injection, and pH adjuster (hydrochloric acid) were prepared in the amounts shown in Table 14, filled into vials, and sealed with a butyl rubber stopper. 57 and 58 solutions are obtained.
- Examples 59 to 66 In the same manner as in Example 1, peptide (1), peptide (2), trehalose, D-mannitol, L-methionine, tartaric acid, water for injection, and pH adjuster (hydrochloric acid) were prepared in the amounts shown in Table 15 or 16. The solution of Examples 59 to 66 is obtained by filling the vial and sealing with a butyl rubber stopper.
- Examples 1A to 66A The solution or suspension prepared in Examples 1, 4, 6, 9, 11, 13, 14, 16, 17, 19, 20, 51, 53, 54 and 57 to 66 was filled into glass vials and then lyophilized. And lyophilize to obtain lyophilized formulations of Examples 1A, 4A, 6A, 9A, 11A, 13A, 14A, 16A, 17A, 19A, 20A, 51A, 53A, 54A and 57A-66A.
- freeze-drying after freezing the liquid or suspension at around ⁇ 40 ° C., the inside of the cabinet is depressurized to vacuum, and at the same time, the inside temperature is raised to around ⁇ 20 ° C. and dried for about 20 hours.
- the temperature is increased to around 30 ° C. and dried for about 12 hours.
- the solutions prepared in Examples 2, 3, 5, 7, 8, 10, 12, 15, 18, 21 to 50, 52, 55 and 56 they were put into a freeze dryer and freeze-dried.
- the lyophilized formulations of Examples 2A, 3A, 5A, 7A, 8A, 10A, 12A, 15A, 18A, 21A-50A, 52A, 55A and 56A were obtained.
- the inside of the cabinet is depressurized to vacuum, and at the same time, the inside temperature is raised to around ⁇ 20 ° C. and dried for about 20 hours.
- the inner temperature was raised to around 30 ° C. and dried for about 12 hours.
- Example 4 Confirmation of Specific CTL Inducing Activity Containing peptide (1), trehalose, D-mannitol, methionine, water for injection, pH adjusting agent (hydrochloric acid) having the same composition ratio as in Example 51, and adjusting the pH
- the liquid agent of Example 67 adjusted to 2.7 was obtained. 2 mL of the solution of Example 67 was filled in a vial, placed in a freeze dryer, and freeze-dried to obtain a freeze-dried preparation of Example 67A.
- a cancer vaccine composition was prepared by mixing with an adjuvant using the lyophilized formulation of Example 67A containing peptide (1) and the lyophilized formulation of Example 55A containing peptide (2).
- Example 67A when the stability of the freeze-dried preparation of Example 67A was evaluated in the same manner as in Test Example 2, the relative purity (relative to the initial value) after storage at 25 ° C. for 3 months was 100%, and a stable preparation was obtained. I was able to.
- Example 55A containing peptide (2) was redissolved in 1.2 mL of water for injection. 1 mL of the redissolved preparation was collected, added to the lyophilized preparation of Example 67A containing peptide (1), and redissolved to prepare a liquid preparation of Example 68. 0.9 mL of this solution was mixed and emulsified with 0.9 mL of adjuvant montanide to obtain a cancer vaccine composition of Example 67.
- HLA-A * 02 01 transgenic mice
- HLA-A * 24 02 transgenic mice
- HLA-A * 02 01 transgenic mice
- HLA-A * 02 01 transgenic mice
- human MHC HLA-A * 02 01 and mouse MHC H-2D b
- HLA-A * 24:02 transgenic mice C57BL / 6CrHLA-A2402 / K b is expressing chimeric HLA of H-2K b are HLA-A * 24:02 and murine MHC is a human MHC
- the above-mentioned cancer vaccine composition was administered at 2 sites at 50 ⁇ L / site in the ridge skin of mice.
- IFN ⁇ ELISPOT assay kit was used.
- mice were euthanized with CO 2 gas, and then the spleen was removed to prepare spleen cells.
- ELISPOT plates were treated with anti-mouse IFN ⁇ antibody and blocked on RPMI 1640 medium containing 10% FBS on the day.
- prepared HLA-A * 02:01 transgenic mice Spleen cells 1.25 ⁇ 10 5 cells / well
- the peptide (SEQ ID NO: 3, 5) was dissolved in DMSO to 40 mg / mL, and further diluted to 40 ⁇ g / mL in RPMI 1640 medium containing 10% FBS.
- the diluted peptide at a final concentration of 10 ⁇ g / mL, HLA-A * 02:01 transgenic mice Spleen cells seeded in ELISPOT plates (SEQ ID NO: 3) or HLA-A * 24:02 transgenic mice Spleen Added to cells (SEQ ID NO: 5). Thereafter, in vitro peptide restimulation was applied by culturing at 37 ° C. under 5% CO 2 for 18 to 20 hours.
- a suspension having good suspendability containing a WT1 protein-derived cancer antigen peptide and a highly stable lyophilized preparation obtained by lyophilizing the suspension.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
(a)式(1):
で表されるペプチド、Trp-Ala-Pro-Val-Leu-Asp-Phe-Ala-Pro-Pro-Gly-Ala-Ser-Ala-Tyr-Gly-Ser-Leu(配列番号:1)で表されるアミノ酸配列からなるペプチドおよびそれらの塩から選択される1種以上のペプチド、
(b)トレハロースまたはトレハロース水和物、および
(c)pH調整剤。
(a)式(1):
で表されるペプチド、Trp-Ala-Pro-Val-Leu-Asp-Phe-Ala-Pro-Pro-Gly-Ala-Ser-Ala-Tyr-Gly-Ser-Leu(配列番号:1)で表されるアミノ酸配列からなるペプチドおよびそれらの塩から選択される1種以上のペプチド
の安定性を向上させる方法であって、上記成分(a)、ならびに以下の成分(b)および(c):
(b)トレハロースまたはトレハロース水和物
(c)pH調整剤
を該組成物中に配合させることを含む、方法。
(a)式(1):
で表されるペプチド、Trp-Ala-Pro-Val-Leu-Asp-Phe-Ala-Pro-Pro-Gly-Ala-Ser-Ala-Tyr-Gly-Ser-Leu(配列番号:1)で表されるアミノ酸配列からなるペプチドおよびそれらの塩から選択される1種以上のペプチド
の安定性を向上させる方法であって、上記成分(a)、ならびに以下の成分(b)、(c)および(d):
(b)トレハロースまたはトレハロース水和物
(c)pH調整剤
(d)メチオニン
を該組成物中に配合させることを含む、方法。
AlaまたはA:アラニン残基
ArgまたはR:アルギニン残基
AsnまたはN:アスパラギン残基
AspまたはD:アスパラギン酸残基
CysまたはC:システイン残基
GlnまたはQ:グルタミン残基
GluまたはE:グルタミン酸残基
GlyまたはG:グリシン残基
HisまたはH:ヒスチジン残基
IleまたはI:イソロイシン残基
LeuまたはL:ロイシン残基
LysまたはK:リジン残基
MetまたはM:メチオニン残基
PheまたはF:フェニルアラニン残基
ProまたはP:プロリン残基
SerまたはS:セリン残基
ThrまたはT:スレオニン残基
TrpまたはW:トリプトファン残基
TyrまたはY:チロシン残基
ValまたはV:バリン残基
Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu(配列番号:3)で表されるアミノ酸配列からなるペプチドとは、ウィルムス腫瘍の癌抑制遺伝子WT1の遺伝子産物であるタンパク質(具体的には、449個のアミノ酸からなるヒトのWT1タンパク質(配列番号:2))のN末端から126番目のアルギニン(Arg)から134番目のロイシン(Leu)までの9個の連続するアミノ酸からなる部分ペプチド(WT1126-134ペプチド)である。当該ペプチドは、MHCクラスI抗原に提示されかつCTLにより抗原認識されるペプチドである。
Cys-Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu(配列番号:5)で表されるアミノ酸配列からなるペプチドとは、WT1タンパク質のN末端から235番目のシステイン(Cys)から243番目のロイシン(Leu)までの9個の連続するアミノ酸からなる部分ペプチド(WT1235-243ペプチド)において、そのN末端から2番目のアミノ酸をメチオニン(Met)からチロシン(Tyr)に改変した改変ペプチドである。当該ペプチドは、MHCクラスI抗原に提示されかつCTLにより抗原認識されるペプチドである。
上記方法で得られる本発明のペプチドが遊離体である場合には、該遊離体を公知の方法あるいはそれに準じる方法によって適当な塩に変換することができるし、逆に本発明のペプチドが塩として得られた場合には、該塩を公知の方法あるいはそれに準じる方法によって遊離体または他の塩に変換することができる。
(b)トレハロースまたはトレハロース水和物
(c)pH調整剤
を含有することを特徴とする。
また、別の観点から、成分(a)がペプチド(2)である場合、pH調整剤において酸としては弱酸が好ましい。
本発明の注射用医薬組成物がペプチド(1)のみを含有する場合、本発明の液状製剤のpHは1~10である。液状製剤が液剤の場合、溶解度および安定性の観点から好ましいpHは1~4であり、さらに好ましくは1~3であり、最も好ましいのは2~3である。液状製剤が懸濁液剤の場合、溶解度の関係からpH5~10が好ましい。上記以外のその他の態様では、液状製剤が液剤の場合、好ましいpHとして、1.5~4.5、1.5~3.5、1.5~3.0、2.0~3.0が挙げられ、懸濁液剤の場合、好ましいpHとして、4~9、4~6、5~9が挙げられる。
一方、本発明の注射用医薬組成物がペプチド(2)のみを含有する場合、本発明の液状製剤のpHは2~10であり、より具体的な範囲として、2~3、3~9、6~9、7である。安定性の観点から好ましいpHは5~10であり、さらに好ましくは6~8である。
さらに、本発明の注射用医薬組成物がペプチド(1)とペプチド(2)とを含有する場合、本発明の液状製剤のpHは2~10である。液状製剤が液剤の場合、安定性の観点から好ましいpHは2~4、2~3、1.7~3.2、および1.5~3.5が挙げられる。
本明細書における数字は記載している数字の一つ下の桁を四捨五入して表す。例えば、2であれば1.5以上2.5未満をさす。
本発明の液状製剤がpH調整剤を含まない場合に、所望のpH範囲より低いpH値を示す場合、pH調整剤として無機塩基または有機塩基を用いることができる。無機塩基および有機塩基としては、上記のものを用いることができる。本発明の注射用医薬組成物がペプチド(2)のみを含有する場合には、pH調整剤として無機塩基または有機塩基を用いることが好ましい。具体的には、リン酸水素二ナトリウム、トロメタモール、ヒスチジン、L-アルギニン、およびメグルミン等が挙げられる。好ましくはリン酸水素二ナトリウム、トロメタモール、L-アルギニン、およびメグルミンである。本発明の注射用医薬組成物において、有機塩基の組成物における重量あたりの含有量は特に規定はないが、本発明の液状製剤における重量あたりの含有量としては、1~100mg/g、1~50mg/g、1~150mg/g、5~100mg/g、5~50mg/g、5~150mg/g、10~100mg/g、10~50mg/g、および10~150mg/g等が挙げられる。
本発明における「マンニトール」とは、糖アルコールの一種であり、ヘキシトールに分類され、マンノースの還元体に相当するものを表す。マンニトールには光学異性体が存在し、D体、L体またはDL体があるが、これらのうちのどれを使用しても本発明の効果に影響はない。好ましくは天然に多く存在するD-マンニトールである。また、マンニトールには複数の結晶系があるが、これらのうちのどれを使用しても本発明の効果に影響はない。本発明の注射用医薬組成物において、マンニトールの組成物における重量あたりの含有量は特に規定はないが、本発明の液状製剤における重量あたりの含有量としては、1~20mg/g、1~30mg/g、1~50mg/g、3~20mg/g、3~30mg/g、5~20mg/g、および5~30mg/g等が挙げられる。
本発明の「メチオニン」は必須アミノ酸のひとつで、側鎖に硫黄原子を含んだ疎水性のアミノ酸である。「メチオニン」には光学異性体が存在し、D体、L体またはDL体があるが、これらのうちのどれを使用しても本発明の効果に影響はない。医薬品に多くの添加物としての使用前例があり、日本薬局方(第16改正)に記載されているL体が好ましい。本発明の注射用医薬組成物において、メチオニンの組成物における重量あたりの含有量は特に規定はないが、好ましくは本発明の液状製剤における重量あたりの含有量としては、1~5mg/g、1~10mg/g、1~20mg/g、1~30mg/g、3~10mg/g、3~20mg/g、3~30mg/g、5~10mg/g、5~20mg/g、および5~30mg/g等が挙げられる。
ペプチド(1)とペプチド(2)の両方を含有する本発明の液状製剤は、両ペプチドを上記の製法に供することで、直接(一段階で)調製することもできるし、各ペプチドを上記の製造に供して、別個の液剤または懸濁液剤として調製した後、両者を混合することにより得ることもできる。好ましい一実施態様においては、ペプチド(1)を含有する液剤または懸濁液剤を凍結乾燥し、これにペプチド(2)を含有する液剤または懸濁液剤を加えて、ペプチド(1)を含有する凍結乾燥製剤を溶解もしくは懸濁する方法が挙げられる。あるいは、各ペプチドを含有する2種の凍結乾燥製剤を調製した後、ペプチド(2)を含有する凍結乾燥製剤を凍結乾燥前の液剤または懸濁液剤よりも少量の水等で再溶解もしくは再懸濁し、該溶液または懸濁液を、ペプチド(1)を含有する凍結乾燥製剤に添加して溶解もしくは懸濁することで、凍結乾燥前の液剤または懸濁液剤よりも高濃度の液剤または懸濁液剤として調製することができる。
Trp-Ala-Pro-Val-Leu-Asp-Phe-Ala-Pro-Pro-Gly-Ala-Ser-Ala-Tyr-Gly-Ser-Leu(配列番号:1)で表されるアミノ酸配列からなるペプチド(ペプチド(2))として、特許文献(WO2010/123065号)に記載されている方法で製造したペプチドを用い、トレハロースとして、トレハロース水和物である「トレハロースSG(林原生物化学研究所製)」を用い、D-マンニトールとして「マンニットS(三菱商事フードテック社製)もしくはD-(-)-Mannitol low in endotoxins(メルク社製)」を用いた。トロメタモールとして「トロメタモール(ナカライテスク社製)」を用い、ヒスチジンとして「ヒスチジン(ナカライテスク社製)」を用い、L-アルギニンとして「L-アルギニン塩酸塩(ナカライテスク社製)」を用い、メグルミンとして「メグルミン(ナカライテスク社製)」を用いた。乳酸として「乳酸(ナカライテスク社製)」を用い、酒石酸として「L(+)-Tartaric acid, powder(メルク社製)」を用い、クエン酸として「くえん酸一水和物(ナカライテスク社製)」を用いた。メチオニンとして「L-メチオニン(協和発酵バイオ社製)」を用いた。pH調整剤として、塩酸としては「1mol/l-塩酸(ナカライテスク社製)」を用い、水酸化ナトリウムとしては「1mol/l-水酸化ナトリウム溶液(ナカライテスク社製)」を用い、リン酸二水素ナトリウムとして「りん酸二水素ナトリウム二水和物(ナカライテスク社製)」を用いた。モンタナイドとして「(Montanide ISA 51 VG(SEPPIC社製)」を用いた。
式(1)で表されるペプチド(ペプチド(1))の合成
(C(Npys)RMFPNAPYLの合成)
Fmoc-Leu-Alko-樹脂(Alkoはp-アルコキシベンジルアルコール)282mg(渡辺化学製;0.71mmol/g、0.2mmol)を出発原料としFmoc/tBu法による固相合成によりペプチド鎖の組上げを行った。固相合成にはCS Bio社製CS336X型ペプチド合成機を用い、Fmoc基の脱保護は20%ピペリジンのDMF溶液で5分間および20分間処理することにより行った。保護アミノ酸のカップリングは1.05mmolの保護アミノ酸、1mmolのHBTU、2mmolのDIPEAのDMF溶液と1時間反応させることにより行った。得られた樹脂をDMFおよびエーテルで洗浄後減圧乾燥することにより、Boc-Cys(Npys)-Arg(Pmc)-Met-Phe-Pro-Asn(Trt)-Ala-Pro-Tyr(tBu)-Leu-Alko-樹脂630mgを得た。このペプチド樹脂にTFA/H2O/TIS=95/2.5/2.5の混合液10mlを加え、室温にて2時間振とうした。樹脂を濾去後、反応液を減圧濃縮した。反応液を氷冷しジエチルエーテル50mlを加えた。生じた沈殿物を濾取しエーテルで洗浄後減圧乾燥することにより粗ペプチド217mgを得た。得られた粗ペプチド溶液を20%酢酸水7mlとアセトニトリル1mlの混合液に溶解し逆相HPLCにて精製した。
ポンプ:Shimazu製;LC-8A型
カラム:YMC ODS-A 3cmφ×25cmL, 10μm
溶出液1:H2O/0.1%TFA
溶出液2:CH3CN/0.1%TFA
流速:20ml/min
検出:UV220nm
2液濃度15%で平衡化させたカラムに粗ペプチド溶液を注入した。その後2液濃度を10分間で37%に上昇させ、その後1分間あたり0.24%の割合で上昇させた。目的物を含む画分を集め凍結乾燥することにより、H-Cys(Npys)-Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu-OH 53mgを得た。
質量分析:LC-ESI/MS m/z =1366.1 [M+1]+ (理論値=1366.6)
〔すなわち式(1):
で表される化合物の合成〕
工程1で得たH-Cys(Npys)-Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu-OH 50mgと公知の方法(例えばWO07/063903)で合成したH-Cys-Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu-OH(すなわちCYTWNQMNL(配列番号:4)) 43mgを混合し、DMSO 1mLを加え、室温にて20分間攪拌した。反応液を0.1%TFA水 5mlで希釈し逆相HPLCにて精製した。
ポンプ:Shimazu製;LC-8A型
カラム:YMC ODS-A 3cmφ×25cmL, 10μm
溶出液1:H2O/0.1%TFA
溶出液2:CH3CN/0.1%TFA
流速:20ml/min
検出:UV220nm
2液濃度25%で平衡化させたカラムに当該反応液を注入した。その後2液濃度を1分間あたり0.25%の割合で上昇させた。目的物を含む画分を集め凍結乾燥した後、逆相HPLCによる再精製、凍結乾燥を行うことにより、(H-Cys-Tyr-Thr-Trp-Asn-Gln-Met-Asn-Leu-OH)(H-Cys-Arg-Met-Phe-Pro-Asn-Ala-Pro-Tyr-Leu-OH) disulfide bond(すなわち式(1)で示されるペプチド(ペプチド(1)) 21mgを得た。
質量分析:LC-ESI/MS m/z =1191.8 [M+2]2+ (理論値=1191.9)
〔実施例1〕
ペプチド(成分(a))として上記ペプチド(1)、成分(b)としてトレハロースを表1に記載の量となるよう注射用水に溶解させ、pH調整剤(成分(c))として、塩酸および/または水酸化ナトリウムでpHを1に調整した。0.2μmの滅菌フィルターを通してろ過した後、ガラス製バイアルに1mLずつ充填し、ブチルゴム栓で密封した。これにより、実施例1の液剤を得た。
実施例1と同様に、ペプチド(1)、トレハロース、pH調整剤(塩酸および/または水酸化ナトリウム)、注射用水を表1または2に記載の量で調製し、バイアルに充填し、ブチルゴム栓で密封することにより実施例2、3、5~8および10の液剤を得た。
実施例1と同様に、ペプチド(1)、トレハロース、pH調整剤(塩酸および/または水酸化ナトリウム)、注射用水を表1または2に記載の量で調製し、バイアルに充填し、ブチルゴム栓で密封することにより実施例4および9の液剤を得る。
実施例1と同様に、成分(a)として配列番号:1(WAPVLDFAPPGASAYGSL)で示されるペプチド(以下、ペプチド(2))、トレハロース、pH調整剤(塩酸および/または水酸化ナトリウム)、注射用水を表3または4に記載の量で調製し、バイアルに充填し、ブチルゴム栓で密封することにより実施例12、15および18の液剤を得た。
実施例1と同様に、成分(a)として配列番号:1(WAPVLDFAPPGASAYGSL)で示されるペプチド(以下、ペプチド(2))、トレハロース、pH調整剤(塩酸および/または水酸化ナトリウム)、注射用水を表3または4に記載の量で調製し、バイアルに充填し、ブチルゴム栓で密封することにより実施例11、13、14、16、17および19の液剤を得る。
実施例1と同様に、ペプチド(1)、トレハロース、D-マンニトール、注射用水、pH調整剤(塩酸および/または水酸化ナトリウム)を表5に記載の量で調製し、バイアルに充填し、ブチルゴム栓で密封することにより実施例20~24の液剤を得た。
適量の注射用水にペプチド(1)、トレハロースを表6に記載の量で調製し、加えて攪拌機で分散後、pH調整剤として、塩酸および/または水酸化ナトリウムでpHを4に調整することで実施例25の懸濁液剤を得た。
実施例25と同様に、適量の注射用水にペプチド(1)、トレハロースを表6に記載の量で調製し、表6に記載のpH調整剤を用いて、表6のpHに調整することで実施例26~29の懸濁液剤を得た。
ペプチド(成分(a))としてペプチド(2)、トレハロース(成分(b))、pH調整剤(成分(c))として、トロメタモールを表7に記載の量となるよう注射用水に溶解させる。0.2μmの滅菌フィルターを通してろ過した後、ガラス製バイアルに1mLずつ充填し、ブチルゴム栓で密封する。これにより、実施例30の液剤を得た。
実施例30と同様に、ペプチド(2)、トレハロース、pH調整剤、注射用水を表7に記載の量で調製し、バイアルに充填し、ブチルゴム栓で密封することにより実施例31~34の液剤を得た。
実施例1と同様に、ペプチド(2)、トレハロース、溶解補助剤(クエン酸、乳酸、酒石酸)、pH調整剤(塩酸)、注射用水を表8に記載の量で調製し、バイアルに充填し、ブチルゴム栓で密封することにより実施例35~37の液剤を得た。
実施例1と同様に、ペプチド(2)、トレハロース、溶解補助剤(酒石酸)、pH調整剤(塩酸)、注射用水を表9または10に記載の量で調製し、バイアルに充填し、ブチルゴム栓で密封することにより実施例38~43の液剤を得た。
実施例1と同様に、ペプチド(2)、トレハロース、溶解補助剤(酒石酸)、pH調整剤(塩酸)、注射用水を表11に記載の量で調製し、バイアルに充填し、ブチルゴム栓で密封することにより実施例44~47の液剤を得た。
実施例1と同様に、ペプチド(1)、トレハロース、D-マンニトール、注射用水、pH調整剤(塩酸)を表12に記載の量で調製し、バイアルに充填し、ブチルゴム栓で密封することにより実施例48~50の液剤を得た。
実施例1と同様に、ペプチド(1)、トレハロース、D-マンニトール、メチオニン、注射用水、pH調整剤(塩酸)を表13に記載の量で調製し、バイアルに充填し、ブチルゴム栓で密封することにより実施例52の液剤を得た。
実施例1と同様に、ペプチド(1)、トレハロース、D-マンニトール、メチオニン、注射用水、pH調整剤(塩酸)を表13に記載の量で調製し、バイアルに充填し、ブチルゴム栓で密封することにより実施例51、53および54の液剤を得る。
実施例1と同様に、ペプチド(2)、トレハロース、酒石酸、注射用水、pH調整剤(塩酸)を表14に記載の量で調製し、バイアルに充填し、ブチルゴム栓で密封することにより実施例55および56の液剤を得た。
実施例1と同様に、ペプチド(2)、トレハロース、酒石酸、注射用水、pH調整剤(塩酸)を表14に記載の量で調製し、バイアルに充填し、ブチルゴム栓で密封することにより実施例57および58の液剤を得る。
実施例1と同様に、ペプチド(1)、ペプチド(2)、トレハロース、D-マンニトール、L-メチオニン、酒石酸、注射用水、pH調整剤(塩酸)を表15または16に記載の量で調製し、バイアルに充填し、ブチルゴム栓で密封することにより実施例59~66の液剤を得る。
〔実施例1A~66A〕
実施例1、4、6、9、11、13、14、16、17、19、20、51、53、54および57~66で製造した液剤または懸濁液剤をガラスバイアルに充填後、凍結乾燥機に入れ、凍結乾燥を行い、実施例1A、4A、6A、9A、11A、13A、14A、16A、17A、19A、20A、51A、53A、54Aおよび57A~66Aの凍結乾燥製剤を得る。なお、凍結乾燥は、-40℃付近で液体または懸濁液剤を凍結させた後、庫内を真空に減圧し、同時に、庫内の温度を-20℃付近に上昇させて20時間程度乾燥させ、さらに、庫内の温度を30℃付近に上昇させて12時間程度乾燥させる条件により、実施する。
実施例2、3、5、7、8、10、12、15、18、21~50、52、55および56で製造した液剤をガラスバイアルに充填後、凍結乾燥機に入れ、凍結乾燥を行い、実施例2A、3A、5A、7A、8A、10A、12A、15A、18A、21A~50A、52A、55Aおよび56Aの凍結乾燥製剤を得た。なお、凍結乾燥は、-40℃付近で液剤を凍結させた後、庫内を真空に減圧し、同時に、庫内の温度を-20℃付近に上昇させて20時間程度乾燥させ、さらに、庫内の温度を30℃付近に上昇させて12時間程度乾燥させる条件により、実施した。
実施例2、3、5、7、8、10、12、15、18、21~26、30~34および52の液剤を25℃で1週間保存後、純度を評価した。純度は、C18逆相カラム(2.1mm×150mm、1.7μmまたは4.6mm×150mm、5μm)を用い、純水、アセトニトリル、トリフルオロ酢酸を移動相に用いた逆相高速液体クロマトグラフィー法(検出波長:220nm)により測定した。本法で測定したピーク面積を用いて、以下の式によりペプチド純度および開始時の純度を100%とした場合の相対純度(対initial値)を算出した。
ペプチド純度(%)=ペプチドのピーク面積/類縁物質を含む総ピーク面積×100
相対純度(対initial値)(%)=保存時点のペプチド純度/開始時のペプチド純度×100
結果を表17に示す。どの製剤も25℃1週間で80%以上あり、安定な製剤を得ることができた。
実施例5A、10A、12A、15A、18A、23A~26A、30A~43A、48A~50A、52A、55Aおよび56Aの凍結乾燥製剤を60℃で2週間保存後、注射用水を加え、液剤にした後、純度を評価した。純度は試験例1と同様に測定し算出した。
結果を表18に示す。どの製剤も60℃2週間で80%以上あり、安定な製剤を得ることができた。
実施例44A~47Aの凍結乾燥製剤を40℃で1ヶ月保存後、注射用水を加えて復水した時の溶解性を目視にて確認した。結果を表19に示す。表19の結果から、溶解補助剤である酒石酸を予め添加しておくことで再溶解性が向上することが示唆された。
実施例51と同一の組成比からなる、ペプチド(1)、トレハロース、D-マンニトール、メチオニン、注射用水、pH調整剤(塩酸)を含み、pHを2.7に調整した実施例67の液剤を得た。実施例67の液剤をバイアルに2mL充填し、凍結乾燥機に入れ、凍結乾燥を行い、実施例67Aの凍結乾燥製剤を得た。ペプチド(1)を含む実施例67Aの凍結乾燥製剤およびペプチド(2)を含む実施例55Aの凍結乾燥製剤を用いて、アジュバントと混合することにより癌ワクチン組成物を調製した。また、実施例67Aの凍結乾燥製剤の安定性を試験例2と同様に評価したところ、25℃で3ヶ月保存後の相対純度(対initial値)は100%であり、安定な製剤を得ることができた。
ペプチド(2)を含む実施例55Aの凍結乾燥製剤を1.2mLの注射用水で再溶解した。再溶解した製剤を1mL採取し、ペプチド(1)を含む実施例67Aの凍結乾燥製剤に加え、再溶解し、実施例68の液剤を作製した。この液剤0.9mLにアジュバントであるモンタナイドを0.9mL混合・乳化し、実施例67の癌ワクチン組成物とした。
上記癌ワクチン組成物のCTL誘導能を、HLA-A*02:01遺伝子導入マウスおよびHLA-A*24:02遺伝子導入マウスを用いたin vivoCTL誘導試験によって評価した。
HLA-A*02:01遺伝子導入マウス(C57BL/6CrHLA-A2.1DR1)は、マウスのMHCを欠損し、ヒトのMHCであるHLA-A*02:01とマウスMHCであるH-2DbのキメラHLA、およびHLA-DRB1*01:01を発現するマウスであり、本マウスを用いることで、HLA-A*02陽性のヒトでCTLを誘導し得るペプチドの選択が可能である(Eur J Immunol.2004;34:3060-9)。一方、HLA-A*24:02遺伝子導入マウス (C57BL/6CrHLA-A2402/Kb)は、ヒトのMHCであるHLA-A*24:02とマウスMHCであるH-2KbのキメラHLAを発現するマウスであり、本マウスを用いることで、HLA-A*24陽性のヒトでCTLを誘導し得るペプチドの選択が可能である(Int J Cancer.2002;100:565-70)。
上記癌ワクチン組成物を、マウスの尾根部皮内に50μL/siteで2箇所に投与した。癌ワクチン組成物のペプチド特異的T細胞誘導評価では、IFNγ ELISPOT assay kitを用いた。投与1週間後に、マウスをCO2ガスにより安楽死させたのち脾臓を摘出し、脾細胞を調製した。脾細胞調製の前日に、ELISPOTプレートを抗マウスIFNγ抗体で処理し、当日に10%FBSを含むRPMI1640培地でブロッキングした。調製したHLA-A*02:01遺伝子導入マウス由来の脾細胞を1.25×105cells/wellで、調製したHLA-A*24:02遺伝子導入マウス由来の脾細胞を5×105cells/wellで、それぞれブロッキングしたELISPOTプレートに播種した。ペプチド(配列番号:3、5)をDMSOで40mg/mLに溶解し、さらに10%FBSを含むRPMI1640培地で40μg/mLに希釈した。希釈したペプチドを最終濃度10μg/mLで、ELISPOTプレートに播種したHLA-A*02:01遺伝子導入マウス由来の脾細胞(配列番号:3)あるいはHLA-A*24:02遺伝子導入マウス由来の脾細胞(配列番号:5)に添加した。その後、18~20時間、37℃、5% CO2下で培養することで、in vitroにおけるペプチド再刺激を加えた。培養後に上清を除き、ELISPOTプレートを、添付のプロトコールに従って発色させた。発色したスポット数は、ImmunoSpot Analyzer(C.T.L.社製)によって測定した。
HLA-A*02:01遺伝子導入マウスを用いたIFNγ ELISPOT assayの結果を図1、HLA-A*24:02遺伝子導入マウス用いたIFNγ ELISPOT assayの結果図2に示す。
図1および2において、縦軸は播種細胞数中に反応した細胞数を、横軸はin vitroでパルスしたペプチドを示す。図1の黒棒はHLA-A*02:01遺伝子導入マウス由来の脾細胞を配列番号:3で表されるペプチドをパルスしながら培養した結果を示し、白棒は非パルスで培養した結果を示す。即ち、黒棒と白棒の値の差がペプチド特異的CTLの数を示し、上記癌ワクチン組成物の投与によってマウス生体内において配列番号:3で表されるペプチドに特異的なCTLが誘導されたことを示す。図1において白棒の値は認められていない。このことは目的のペプチドをパルスしない場合にはHLA-A*02:01遺伝子導入マウスの脾細胞は全く反応しなかったことを示している。本試験の結果、HLA-A*02:01遺伝子導入マウス由来の脾細胞において配列番号:3で表されるペプチドに特異的なIFNγの産生が確認された。
さらに、図2の黒棒はHLA-A*24:02遺伝子導入マウス用いた由来の脾細胞を配列番号:5で表されるペプチドをパルスしながら培養した結果を示し、白棒は非パルスで培養した結果を示す。即ち、黒棒と白棒の値の差がペプチド反応性細胞の数を示し、上記癌ワクチン組成物の投与によってマウス生体内において配列番号:5で表されるペプチドに特異的なCTLが誘導されたことを示す。図2において白棒の値は認められていない。このことは目的のペプチドをパルスしない場合にはHLA-A*24:02遺伝子導入マウスの脾細胞は全く反応しなかったことを示している。本試験の結果、HLA-A*24:02遺伝子導入マウス由来の脾細胞において配列番号:5で表されるペプチドに特異的なIFNγの産生が確認された。
これにより、上記癌ワクチン組成物はin vivoで配列番号:3および配列番号:5で表されるペプチド特異的なCTLを誘導し得ることが明らかとなった。したがって、ペプチド(1)を含むペプチドが安定な製剤とペプチド(2)を含むペプチドが安定な製剤を再調製した製剤は、癌ワクチンとして使用できることが示唆される。
Claims (22)
- 成分(a)が式(1)で表されるペプチドおよびその塩から選択される1種以上のペプチドである、請求項1に記載の組成物。
- さらにマンニトールを含むことを特徴とする、請求項2に記載の組成物。
- マンニトールがD-マンニトールである、請求項3に記載の組成物。
- さらにメチオニンを含むことを特徴とする、請求項2~4のいずれか一項に記載の組成物。
- pHが1~3であることを特徴とする、請求項2~5のいずれか一項に記載の組成物。
- 成分(a)がTrp-Ala-Pro-Val-Leu-Asp-Phe-Ala-Pro-Pro-Gly-Ala-Ser-Ala-Tyr-Gly-Ser-Leu(配列番号:1)で表されるアミノ酸配列からなるペプチドおよびその塩から選択される1種以上のペプチドである、請求項1に記載の組成物。
- さらに溶解補助剤を含むことを特徴とする、請求項7に記載の組成物。
- 溶解補助剤が酒石酸である、請求項8に記載の組成物。
- pHが2~3であることを特徴とする、請求項8または9に記載の組成物。
- pHが5~10であることを特徴とする、請求項7に記載の組成物。
- pH調整剤が塩酸および/または水酸化ナトリウムであることを特徴とする、請求項1~11のいずれか一項に記載の組成物。
- pH調整剤として用いる酸が弱酸であることを特徴とする、請求項7~11のいずれか一項に記載の組成物。
- 成分(a)が、式(1)で表されるペプチドおよびその塩から選択される1種以上のペプチドと、Trp-Ala-Pro-Val-Leu-Asp-Phe-Ala-Pro-Pro-Gly-Ala-Ser-Ala-Tyr-Gly-Ser-Leu(配列番号:1)で表されるペプチドおよびその塩から選択される1種以上のペプチドとを含むことを特徴とする、請求項1に記載の組成物。
- さらにマンニトールを含むことを特徴とする、請求項14に記載の組成物。
- さらにメチオニンを含むことを特徴とする、請求項14または15に記載の組成物。
- さらに溶解補助剤を含むことを特徴とする、請求項14~16のいずれか一項に記載の組成物。
- pHが2~3であることを特徴とする、請求項14~17のいずれか一項に記載の組成物。
- 組成物が液剤、懸濁液剤、または凍結乾燥製剤であることを特徴とする、請求項1~18のいずれか一項に記載の組成物。
- 凍結乾燥製剤の形態である請求項2~6のいずれか一項に記載の組成物に、液剤の形態である請求項7~10のいずれか一項に記載の組成物を加えることにより製造される、請求項14~18のいずれか一項に記載の組成物。
- 液剤または懸濁液剤であることを特徴とする、請求項20に記載の組成物。
- 請求項2~21のいずれか一項に記載の組成物を含む癌ワクチン組成物。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2962630A CA2962630C (en) | 2014-09-27 | 2015-09-26 | Pharmaceutical composition for injection |
DK15844271.5T DK3199175T3 (da) | 2014-09-27 | 2015-09-26 | Farmaceutisk sammensætning til injektion |
ES15844271T ES2916834T3 (es) | 2014-09-27 | 2015-09-26 | Composición farmacéutica para inyección |
US15/514,258 US10471136B2 (en) | 2014-09-27 | 2015-09-26 | Pharmaceutical composition for injection |
JP2016550427A JP6580581B2 (ja) | 2014-09-27 | 2015-09-26 | 注射用医薬組成物 |
EP15844271.5A EP3199175B1 (en) | 2014-09-27 | 2015-09-26 | Pharmaceutical composition for injection |
CN201580052306.4A CN106687129B (zh) | 2014-09-27 | 2015-09-26 | 注射用药物组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014197667 | 2014-09-27 | ||
JP2014-197667 | 2014-09-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016047797A1 true WO2016047797A1 (ja) | 2016-03-31 |
Family
ID=55581312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/077223 WO2016047797A1 (ja) | 2014-09-27 | 2015-09-26 | 注射用医薬組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10471136B2 (ja) |
EP (1) | EP3199175B1 (ja) |
JP (2) | JP6580581B2 (ja) |
CN (1) | CN106687129B (ja) |
CA (1) | CA2962630C (ja) |
DK (1) | DK3199175T3 (ja) |
ES (1) | ES2916834T3 (ja) |
WO (1) | WO2016047797A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020067453A1 (ja) | 2018-09-28 | 2020-04-02 | 大日本住友製薬株式会社 | 注射用組成物 |
WO2023013755A1 (ja) * | 2021-08-06 | 2023-02-09 | ブライトパス・バイオ株式会社 | がんペプチドワクチンカクテル製剤、及びその製造方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102646145B1 (ko) | 2018-05-31 | 2024-03-11 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물 |
JP7079984B2 (ja) | 2018-07-28 | 2022-06-03 | エクソコバイオ インコーポレイテッド | エキソソームの凍結乾燥方法 |
KR102163806B1 (ko) | 2018-07-30 | 2020-10-07 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물 |
WO2020056249A1 (en) | 2018-09-14 | 2020-03-19 | Cara Therapeutics, Inc. | Oral formulations of kappa opioid receptor agonists |
CN115335072A (zh) | 2020-03-18 | 2022-11-11 | 卡拉治疗学股份有限公司 | κ阿片受体激动剂的寡糖配制品 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06135851A (ja) * | 1992-10-26 | 1994-05-17 | Seikagaku Kogyo Co Ltd | コンドロイチナーゼ組成物およびそれを含有する注射用製剤 |
JP2000229882A (ja) * | 1998-12-10 | 2000-08-22 | Sankyo Co Ltd | 修飾シクロデキストリン含有トロンビン水性液剤 |
WO2003097083A1 (fr) * | 2002-05-21 | 2003-11-27 | Daiichi Suntory Pharma Co.,Ltd. | Compositions medicinales contenant de la ghreline |
US20070191271A1 (en) * | 2006-02-10 | 2007-08-16 | Dow Pharmaceutical Sciences | Method for stabilizing polypeptides lacking methionine |
WO2010123065A1 (ja) * | 2009-04-23 | 2010-10-28 | 株式会社癌免疫研究所 | 癌抗原ヘルパーペプチド |
WO2014142102A1 (ja) * | 2013-03-12 | 2014-09-18 | 大日本住友製薬株式会社 | 液体水性組成物 |
WO2014157692A1 (ja) * | 2013-03-29 | 2014-10-02 | 大日本住友製薬株式会社 | Wt1抗原ペプチドコンジュゲートワクチン |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5496718A (en) | 1992-06-26 | 1996-03-05 | Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) | Chondroitinase ABC isolated from proteus vulgaris ATCC 6896 |
WO2000006602A1 (fr) | 1998-07-31 | 2000-02-10 | Haruo Sugiyama | Antigenes contre le cancer a base d'un produit du gene suppresseur de tumeur wt1 |
BRPI0208183B8 (pt) | 2001-03-22 | 2021-05-25 | Sugiyama Haruo | peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer |
AU2004204031B2 (en) * | 2003-01-15 | 2010-03-04 | International Institute Of Cancer Immunology, Inc. | Dimerized peptide |
AU2006319892B2 (en) | 2005-11-30 | 2012-05-10 | International Institute Of Cancer Immunology, Inc. | Novel peptide compound |
US20110270212A1 (en) * | 2007-10-05 | 2011-11-03 | Medtronic, Inc. | Pharmacokinetic control for optimized interferon delivery |
EP2226081A4 (en) * | 2007-10-25 | 2011-10-12 | Univ Kagoshima | PEPTIDE VACCINE WITH A MIMIC MOLECULE OF AMYLOID PEPTIDE |
US9539299B2 (en) * | 2011-10-27 | 2017-01-10 | International Institute Of Cancer Immunology, Inc. | Combination therapy with WT1 peptide vaccine and temozolomide |
-
2015
- 2015-09-26 EP EP15844271.5A patent/EP3199175B1/en active Active
- 2015-09-26 US US15/514,258 patent/US10471136B2/en active Active
- 2015-09-26 DK DK15844271.5T patent/DK3199175T3/da active
- 2015-09-26 ES ES15844271T patent/ES2916834T3/es active Active
- 2015-09-26 JP JP2016550427A patent/JP6580581B2/ja active Active
- 2015-09-26 CA CA2962630A patent/CA2962630C/en active Active
- 2015-09-26 CN CN201580052306.4A patent/CN106687129B/zh active Active
- 2015-09-26 WO PCT/JP2015/077223 patent/WO2016047797A1/ja active Application Filing
-
2019
- 2019-08-28 JP JP2019155520A patent/JP6941143B2/ja active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06135851A (ja) * | 1992-10-26 | 1994-05-17 | Seikagaku Kogyo Co Ltd | コンドロイチナーゼ組成物およびそれを含有する注射用製剤 |
JP2000229882A (ja) * | 1998-12-10 | 2000-08-22 | Sankyo Co Ltd | 修飾シクロデキストリン含有トロンビン水性液剤 |
WO2003097083A1 (fr) * | 2002-05-21 | 2003-11-27 | Daiichi Suntory Pharma Co.,Ltd. | Compositions medicinales contenant de la ghreline |
US20070191271A1 (en) * | 2006-02-10 | 2007-08-16 | Dow Pharmaceutical Sciences | Method for stabilizing polypeptides lacking methionine |
WO2010123065A1 (ja) * | 2009-04-23 | 2010-10-28 | 株式会社癌免疫研究所 | 癌抗原ヘルパーペプチド |
WO2014142102A1 (ja) * | 2013-03-12 | 2014-09-18 | 大日本住友製薬株式会社 | 液体水性組成物 |
WO2014157692A1 (ja) * | 2013-03-29 | 2014-10-02 | 大日本住友製薬株式会社 | Wt1抗原ペプチドコンジュゲートワクチン |
Non-Patent Citations (3)
Title |
---|
JAIN, N. K. ET AL.: "Trehalose and protein stability", CURRENT PROTOCOLS IN PROTEIN SCIENCE, no. Suppl. 59., 2010, pages 4.9.1 - 4.9.12, XP055145633 * |
JAPAN PHARMACEUTICAL EXCIPIENTS COUNCIL: "Iyakuhin Tenkabutsu Jiten, first edition", part f irst edition 1994, pages: 65, XP009501416 * |
See also references of EP3199175A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020067453A1 (ja) | 2018-09-28 | 2020-04-02 | 大日本住友製薬株式会社 | 注射用組成物 |
KR20210068060A (ko) | 2018-09-28 | 2021-06-08 | 다이니뽄 스미토모 세이야쿠 가부시키가이샤 | 주사용 조성물 |
JPWO2020067453A1 (ja) * | 2018-09-28 | 2021-09-09 | 大日本住友製薬株式会社 | 注射用組成物 |
US20210338587A1 (en) * | 2018-09-28 | 2021-11-04 | Sumitomo Dainippon Pharma Co., Ltd. | Injectable composition |
JP7162675B2 (ja) | 2018-09-28 | 2022-10-28 | 住友ファーマ株式会社 | 注射用組成物 |
WO2023013755A1 (ja) * | 2021-08-06 | 2023-02-09 | ブライトパス・バイオ株式会社 | がんペプチドワクチンカクテル製剤、及びその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2020015742A (ja) | 2020-01-30 |
JPWO2016047797A1 (ja) | 2017-07-06 |
US10471136B2 (en) | 2019-11-12 |
CA2962630A1 (en) | 2016-03-31 |
JP6580581B2 (ja) | 2019-09-25 |
CN106687129A (zh) | 2017-05-17 |
EP3199175B1 (en) | 2022-03-23 |
CA2962630C (en) | 2023-02-21 |
JP6941143B2 (ja) | 2021-09-29 |
EP3199175A1 (en) | 2017-08-02 |
EP3199175A4 (en) | 2018-05-23 |
US20180344831A1 (en) | 2018-12-06 |
DK3199175T3 (da) | 2022-06-13 |
ES2916834T3 (es) | 2022-07-06 |
CN106687129B (zh) | 2021-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7248247B2 (ja) | Wt1抗原ペプチドコンジュゲートワクチン | |
JP6941143B2 (ja) | 注射用医薬組成物 | |
JP6294868B2 (ja) | 液体水性組成物 | |
JP2019089802A (ja) | Erap1によるトリミング機能をきっかけとしたコンジュゲートワクチン | |
EP3473262A1 (en) | Plexin binding regulator | |
BR112015024583B1 (pt) | Composto, suas composições e seu uso para a produção de um medicamento para o tratamento de câncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15844271 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016550427 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2962630 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015844271 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015844271 Country of ref document: EP |